[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
We used treatment with intra-arterial injection in cases of liver and peritoneal metastasis in progressive or recurrent gastric cancer patients. The investigation of the relationship between efficiency of therapy and survival period was evaluated. The effective rate of sequential treatment of peritoneal metastasis with MTX.5-FU in 34 cases was 35.3%, while that of liver metastasis with MMC combined with DSM in 12 cases was 50%. Although the effective rate among 16 cases treated with MMC.5-FU combined with Angiotensin II was 50%, no effect was recognized in the groups treated with AF and MF. In cases of peritoneal metastasis with MTX.5-FU, the prognosis PR cases was significantly better than that of NC.PD. For treatment of liver metastasis with MMC combined with DSM and MMC.5-FU combined with Angiotensin II, the PR prognosis was unsatisfactory and the survival period did not significantly improve compared with that of NC.PD. In future cases of liver metastasis, these results indicate the extreme difficulty in maintaining therapy and controlling the lesion after PR. We speculated that sequential treatment of peritoneal metastasis with MTX.5-FU was useful because it significantly extended the survival period in PR cases.
Kitamura
M
M
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Arai
K
K
Miyashita
K
K
D000804:Angiotensin II / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D008937:Mitomycins; D000804:Angiotensin II; D016685:Mitomycin; D005472:Fluorouracil